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Abstract 
Objective: The aims of this study were to: investigate the role of angiotensin in mediating changes 
to myocardial electromechanical properties during the development and regression of left 
ventricular hypertrophy (LVH) generated by constriction of the thoracic aorta; and identify any role 
of angiotensin-1 receptor blockade on ameliorating changes to these electromechanical properties. 
Methods: LVH was induced in guinea-pigs by constricting the ascending aorta (AC groups). After 
42±3 days, the constriction was either removed or left in place. Following the second operation 
animals were fed losartan (10 mg·kg-1·day-1) or saline for 42±3 days. Sham-operated animals served 
as controls.  In other groups, LVH was generated by subcutaneous angiotensin II (200 ng·kg-1·min-1) 
infusion for 42±3 days with or without losartan administration (AT groups), and compared to 
animals undergoing aortic constriction for a similar period. Electromechanical changes were 
recorded in isolated left ventricular myocardial preparations.  
Results: Wet and dry heart-to-body weight ratios (HBR) increased significantly in the AC and AT 
models, compared to control.  Losartan prevented the increase of HBR in the AT group. Removal of 
the constriction allowed LVH to regress to control. The force-frequency relationship was reduced in 
both models and recovered fully on regression. However, the two models generated different 
electrophysiological changes: in the AC group longitudinal conduction velocity was reduced and 
transverse conduction increased, with a consequent reduction of the anisotropic conduction ratio: on 
regression recovery was only partial; action potential duration was prolonged and did not recover. 
In the AT group electrophysiological changes were limited, only an increase of transverse 
conduction, and a reduction of the anisotropic conduction ratio were observed. Losartan had no 
effect on HBR or electromechanical variables in the aortic constricted animals, nor did it affect the 
extent of recovery in animals with regression of LVH. 
Conclusions: The electromechanical changes to hypertrophied myocardium are different in these 
two models of LVH.  Moreover, losartan was ineffective in modulating the consequences of 
hypertrophy induced by constriction of the thoracic aorta.  
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Introduction 
Left ventricular hypertrophy (LVH) is a significant predictor of cardiovascular mortality and 
morbidity arising from both ventricular arrhythmias and myocardial failure [1,2].  
Electrophysiological changes occur during hypertrophy, in particular to action potential (AP) 
duration, and to conduction due to alterations of the active and passive electrical properties of the 
myocardium [3-5], and these are likely to contribute to the risk of re-entrant arrhythmias and sudden 
death.   
 
Regression of LVH by pharmacological and surgical procedures has been shown in animal models 
of hypertrophy [6,7] and in humans with aortic stenosis and hypertension [8,9]. However, this is not 
always accompanied by normalisation of the associated pathophysiology, in particular 
electrophysiological abnormalities [6], and indeed the prognosis associated with previous LVH 
remains poor [10].   Furthermore, it is difficult to separate out the effects of drug-induced regression 
of LVH from the action of the drugs themselves or the reduction of blood pressure.  
 
The renin-angiotensin system has been implicated in the development of some models of 
hypertrophy [11], but its involvement in the changes to the physiological properties of myocardium 
that occur during hypertrophy has not been investigated.  Although systemic increases of 
angiotensin (AT) have not been observed in hypertrophy induced by constriction of the thoracic 
aorta [12] it remains possible that AT may mediate some of the functional changes.  The purpose of 
this study was twofold: to investigate the potential role of AT in this context, by comparing the 
electromechanical changes induced in hypertrophied myocardium by aortic constriction or infusion 
of AT; and to determine the role that blockade of angiotensin-1 receptors may play in ameliorating 
the consequences of hypertrophy and reversal of changes on regression of hypertrophy.  
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Methods 
Induction of left ventricular hypertrophy (LVH) and regression from LVH.  Ten groups of adult 
male Dunkin-Hartley guinea-pigs (600-800 g) were used to study the pathophysiology of LVH, 
seven by constriction of the ascending aorta (including sham-operated controls), and three by 
angiotensin infusion: the protocols are shown in figure 1.  The basic treatment block was 42 or 84 
days, as in this model these periods generate LVH without development of heart failure [3,6].  In 
groups 2, 3, 4, 5 and 7 LVH was induced by placing a high-density plastic clip (internal diameter 
2.0 mm) around the ascending aorta. Animals were anaesthetised with Na pentobarbitone (0.12 mg 
Sagatal, Rhone Merieux Ltd, Harlow) and 0.1 mg diazepam for injection (Phoenix Pharma Ltd, 
Gloucester), followed by inhalation of a 49%/49%/2%, N2O/O2/halothane mixture. Animals were 
intubated and ventilated at 100 cycles per minute, with an O2 flow of 0.4 l·min-1 and the aorta 
exposed via a left thoracotomy, as previously described [13].  Groups 1 and 6 were sham-operated 
controls that underwent the same procedures, without clip placement. After 42±3 days, animals in 
groups 6 and 7 were killed, and the hearts removed rapidly for in vitro experiments.  Animals in 
groups 1-5 at this time underwent a right thoracotomy and the plastic clip was either left in place 
(age-matched LVH, groups 2 & 3), removed (de-banded groups 4 & 5), or had a second sham-
operation (group 1). After this second procedure, animals in groups 2 - 5 were daily given an oral 
gavage containing losartan in 1 ml isotonic saline (10 mg·kg-1, Merck, Sharp & Dohme [14], groups 
3 & 5), or saline alone (groups 2 & 4).   
 
With group 9 guinea-pigs, LVH was induced by infusion of angiotensin II for 42±3 days (200 
ng·kg-1·min-1, Sigma; [15]), by subcutaneous osmotic mini-pumps inserted under anaesthesia: group 
8 animals received saline infusion. Finally, group 10 animals also received 42 days of angiotensin 
infusion, with losartan also administered as described above.    
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All procedures conformed to The Guide for the Care and Use of Laboratory Animals (National 
Institute of Health (NIH) Publication No. 85-23, revised 1996) and UK Guidelines in The Operation 
of Animals (Scientific Procedures) Act, 1986. 
 
FIGURE 1 NEAR HERE 
Isolated preparations. Animals were weighed, sacrificed by cervical dislocation and the hearts 
rapidly removed and weighed.  Heart-to-body weight ratio (HBR) was used to assess the extent of 
hypertrophy and regression. Lung-to-body weight ratio was used to assess a lack of heart failure if 
the value was similar in experimental and sham-operated groups.   Parallel cohorts of animals for 
groups 1, 2, 4, 6, 7, 8 and 9 were prepared to measure the dry weight of the left ventricle to test the 
hypothesis that and increase of HBR was due to a greater tissue mass rather than accumulation of 
oedema.  The left and right ventricles were separately weighed, placed in an oven at 80°C and dried 
for 48 hours.     
 
Left ventricular papillary muscles were isolated from experimental hearts, mounted in a superfusion 
bath, secured at one end to a fixed hook and at the other end to an isometric tension transducer, and 
superfused with Tyrodes’s solution at 4 ml·min-1, at 37°C. Tyrode’s contained (mM): NaCl 118, 
KCl 4.0, NaHCO3 24, MgCl2 1.0, CaCl2 1.8, NaH2PO4 0.4, glucose 6.1, Na pyruvate 5.0, pH 
7.40±0.2, gassed with 95% O2 and 5% CO2.  Muscles were up to 6mm long, <2mm wide, and 
<1mm thick to minimise hypoxic damage to the tissue.  
 
The force-frequency relationship was quantified as the ratio of peak isometric tensions generated at 
1.6 and 0.8 Hz stimulation frequencies (T1.6/0.8). Field-stimulated action potentials were recorded 
with 10 MΩ, 3M KCl-filled microelectrodes at 1 Hz.  AP duration was the time from the upstroke 
to 95% repolarisation (APD95). Conduction velocity along the longitudinal axis (θL) was measured 
by stimulating the muscle at one end via insulated Ag-AgCl electrodes, with pulses at 1.5x 
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threshold to minimize extracellular current spread, and recording APs at distances, d, more than 1 
mm from the stimulation site.  The distance d was measured with a Vernier scale on the 
microelectrode micromanipuator, and checked with an eyepiece graticule under x40 magnification, 
both methods were accurate to 100 µm. θL was calculated as the distance:delay ratio over several 
values of d. Transverse conduction velocity, θT, was measured using large extracellular stimulating 
electrodes parallel to the muscle axis, and restricting the extracellular volume, under these 
conditions AP conduction is transverse to the axis [16]. We have shown previously [4,5] that these 
stimulating conditions provide one-dimensional, planar conduction in the axis of interest, with an 
error of < 5% in other dimensions. The time constant of the action potential base or foot, τap, was 
calculated from a semilogarithmic plot of the initial 10-12 mV depolarisation of the conducted AP. 
 
Statistical analyses.  Results are expressed as mean ± SD, or when several separate measurements 
were made from the same preparation as SE. Comparison between groups was assessed using 
ANOVA with Bonferroni post hoc tests.  The null hypothesis was rejected when p<0.05. 
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Results 
Development of cardiac hypertrophy and regression from hypertrophy.  The magnitude of cardiac 
hypertrophy was assessed in two ways: the wet heart-to-body weight ratio (HBR); and the dried left 
ventricular-to-body weight ratio (DLVBR).  Table 1 shows that both variables increased after 
constriction for 42 days (group 7) and 84 days (group 2), with respect to their respective age-
matched controls (groups 6 and 1, respectively).  Furthermore, in the group that was de-banded after 
42 days constriction (group 4) HBR and DLVBR decreased significantly to values not different 
from the age-matched control. HBR and DLVBR after 42 and 84 days constriction were not 
significantly different. Thus, the effect of the debanding procedure after 42 days could be measured 
after ventricular hypertrophy had developed to a steady level.  Table 1 also shows that angiotensin, 
compared to saline, infusion for 42 days (groups 8 & 9) also increased HBR and DLVBR, to values 
similar to the time-matched aortic constriction groups.  Thus, with respect to generation of 
hypertrophy the methods of thoracic aortic constriction and angiotensin infusion produced 
comparable results.   
 
The lung-to-body weight ratio in the combined control groups (sham constriction and saline 
infusion, groups 1, 6 & 8) was 4.44±0.65 g·kg-1; values in all remaining groups were not 
significantly different from this value. 
TABLE 1 NEAR HERE 
 
Electromechanical changes during hypertrophy and its regression.  Table 2 summarises the 
electromechanical properties of myocardium after 84 days aortic constriction, and also after 42 days 
of constriction and 42 days of de-banding, compared to 84-day sham-operated controls.  Some data 
is in confirmation of previous findings [4-6]. It should be noted that the changes to the 84-day 
constricted group were quantitatively similar to changes after 42 days constriction (for the latter see 
‘AC’ data in figure 2B).  Preparations from control animals showed a positive staircase, as 
CVR-2006-391 R2, Gray et al 
 8 
evidenced by values for T1.6/0.8 greater than 1.0.  This variable was significantly reduced in the 
hypertrophied hearts but recovered completely in the regressed hearts.  Absolute twitch strength at 
1Hz, time-to-peak tension and twitch duration were similar in all experimental groups (sham-
operated values were respectively: 2.15±1.40 mN·mm-2; 132±3.7 ms; 289±8.1 ms). 
TABLE 2 NEAR HERE 
 
However, electrophysiological changes associated with LVH showed less complete reversibility.  
Table 2 shows that APD95 was prolonged in hypertrophy and remained so after LVH regression.  
Action potential conduction velocity in the longitudinal axis of the preparation, θL, was reduced in 
LVH, but was increased in the transverse axis, θT, resulting in a reduction of the anisotropic 
conduction ratio, θL/θT.  Regression of hypertrophy only partially ameliorated these conduction 
changes; thus θL only partially recovered to an intermediate value, although transverse conduction, 
θT, returned to control.  The anisotropy ratio also returned to a value not significantly different from 
the control value.  By contrast, the resting membrane potential, Em, was unaffected by LVH and its 
regression.  The maximum rate of action potential (AP) depolarisation (dV/dtmax), and the time 
constant of the action potential foot, τap - factors importantly determined by the magnitude of the 
Na+ current - were also unaltered in LVH and its regression.  dV/dtmax and τap were measured from 
action potentials conducting in the longitudinal (L) or transverse (T) axes. In groups shown in table 
2, and in all other experimental groups, these values were greater in the transverse compared to the 
longitudinal axis; this significance will be considered in the Discussion.  Figure 2A illustrates the 
rising phases of longitudinally and transversely conducting action potentials.  The thicker lines 
(arrowed) drawn over the subthreshold regions of the rising phase indicate the regions used to 
calculate τap.  The delay, d, between the start of the stimulus artefact and the peak of differential 
response (lower traces) was used to calculate conduction velocity – see also figure legend).  All 
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further interventions had no effect on the values of membrane potential, dV/dtmax or τap so their 
values are not further reported. 
 
Effects of angiotensin II infusion.   Table 1 shows that angiotensin II infusion (n=7) also increased 
significantly HBR and DLVBR.  Figure 2B shows the electromechanical properties with 
angiotensin infusion and compares these with aortic constriction for 42 days.  It shows that the 
changes accompanying myocardial hypertrophy were different in the two models. The T1.6/0.8 ratio 
was reduced from 1.55±0.02 to 1.24±0.02, similar to that in the aortic constriction group.  However, 
the prolongation of the action potential, and reduction of longitudinal conduction velocity were 
absent in the angiotensin group, although there was a similar increase of transverse conduction 
velocity and a consequent reduction, albeit smaller, of the anisotropic conduction ratio.  Control 
data from sham-operated (group 6) and saline-infused (group 8) animals were identical; for clarity 
only the latter control data are shown in figure 2.  Figure 2C shows sample action potentials from 
the control, aortic-constricted and angiotensin-infused groups. 
FIGURE 2 NEAR HERE 
 
Effects of the angiotensin II type-1 receptor (AT1) antagonist, losartan, on electromechanical 
changes during hypertrophy.  Forty-two days after initiating aortic constriction, two groups of 
animals were fed losartan: during the continued presence of the constriction (group 3); after 
removal of the constriction (group 5).  The objective was to determine if AT1-receptor antagonism 
influenced changes to myocardial electromechanical properties during these periods.  To determine 
if the losartan dose, and route of administration, were adequate, a control series of experiments was 
carried out whereby losartan was administered during angiotensin infusion via osmotic mini-pumps.  
In three separate experiments losartan administration alone had no effect on HBR (2.66±0.24 vs 
2.44±0.18 g·kg-1, saline vs losartan) or any electromechanical variable (data not shown).   
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Figure 3A shows that losartan prevented the increase of HBR induced by angiotensin infusion 
(group 10 vs group 9 animals); the value of 2.93±0.41 g·kg-1 was significantly less than the 
angiotensin group, and not different from the saline-infusion group.  Furthermore, losartan 
prevented the angiotensin-mediated changes to electromechanical properties reported above, i.e. the 
T1.6/0.8 ratio (1.59±0.08 vs 1.24±0.04, p<0.05, with and without losartan respectively). It may be 
concluded that the administration of losartan effectively antagonised the effect of infused 
angiotensin on cardiac growth and functional myocardial properties. 
FIGURE 3 NEAR HERE 
 
The possible involvement of angiotensin, through a losartan-sensitive mechanism, in altering 
electromechanical function during LVH maintained by aortic constriction was therefore examined. 
Figure 3B shows that 42-days administration of losartan did not reduce HBR.  Furthermore, figure 4 
shows that treatment with losartan had no effect on the variables altered during aortic constriction.  
Thus, the T1.6/0.8 ratio was attenuated, APD95 was prolonged, longitudinal conduction velocity was 
reduced, transverse conduction increased, and the anisotropic conduction ratio decreased: all to 
similar extents to those without losartan. 
FIGURE 4 NEAR HERE 
 
Effects of losartan on electromechanical changes during regression 
Figure 3C shows that 42-days oral administration of losartan after removal of the aortic constriction 
had no influence on the return of HBR to the control value.  Figure 5 also shows that losartan also 
had no effect on the complete recovery of T1.6/0.8 after regression of LVH, and that the action 
potential also remained prolonged.  For reference, the data for the maintained-LVH group are also 
shown.   Equally, longitudinal conduction velocity, θL, only partially recovered in the deconstricted 
group, with or without losartan; the values in both groups were significantly different from both the 
sham-operated and the maintained-LVH groups.  The transverse conduction, and hence the 
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computed conduction anisotropy data were not completely comparable between the de-banded 
groups with and without losartan. With losartan the mean value of transverse conduction velocity 
did reduce after de-banding, but the recovery was statistically incomplete. 
 
It may be concluded that losartan was able to prevent the generation of cardiac hypertrophy induced 
by angiotensin infusion, along with the limited number of electromechanical changes observed in 
this model of cardiac hypertrophy.  However, losartan had no effect on ameliorating the magnitude 
of hypertrophy, and the associated electromechanical changes, after aortic constriction.  
Furthermore, losartan, at least over 42-days administration, had no effect on the regression process, 
in particular the electrophysiological changes that persisted after cardiac size had normalised were 
unaffected by treatment with losartan. 
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Discussion 
Alterations to electromechanical function in LVH and its regression. In confirmation of previous 
work [4,6], constriction of the guinea-pig ascending aorta for about 42 days generated cardiac 
growth as evidenced by a larger heart-to-body weight ratio (HBR) and an increase of dry heart 
weight.  This was completely reversible on removal of the constriction, after a period comparable to 
the constriction phase. Morphological regression was accompanied by recovery of contractile 
function, as evidenced by the staircase response; however, several electrophysiological changes 
either remained (APD) or recovered only partially (conduction velocity).  Whether these variables 
would eventually normalise after a longer period of de-banding is unclear and requires further 
study.  The risk of arrhythmias in humans is not always reduced with regression of LVH [17], 
which may in part be due to incomplete recovery of electrophysiological function. Our study 
concords with a canine model of volume-overload hypertrophy, which showed that despite 
regression of hypertrophy QT interval remained prolonged [18].  In contrast, a feline model of 
pressure-overload hypertrophy showed that with regression of wall thickness, ventricular fibrillation 
thresholds and the ease of induction of ventricular arrhythmias reverted to control levels [19]. 
 
A rise of the intracellular [Na+] is an early characteristic of LVH and we have postulated that this is 
partly responsible for electromechanical changes by indirectly affecting gap junction conductance 
[3,20].  However, this cannot be the sole explanation, because of the heterogenous changes to 
conduction velocity. Our data are consistent with a change also to gap junction redistribution 
around the myocyte, as observed in other models of LVH [21].  However, we do not know the rate 
and extent of recovery of these cellular and morphological changes during regression of LVH.   
 
Of note was a lack of change to the AP upstroke (dV/dtmax), or the time constant of the AP foot (τap) 
associated with any of the interventions.  However, both were hastened in transverse conduction 
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pathways, indicative of discontinuous conduction in the myocardial syncitium [22].  Its significance 
is that reduction of longitudinal conduction velocity in LVH, and the failure to normalise 
completely on regression of LVH, would emphasise the low safety factor in this axis (i.e. increase 
the likelihood of conduction failure), and increase the possibility of re-entrant arrhythmias [23].  
Both dV/dtmax and τap are importantly determined by the magnitude and/or kinetics of the Na+ 
inward current, and implies these did not alter significantly during any intervention.  We propose 
that the persistent changes to conduction in LVH result mainly from alterations to unit gap junction 
conductance and their redistribution around the myocyte.  Moreover it is important to identify 
conditions that may ameliorate the effect of LVH on altered electrophysiological variables, and if 
recovery during regression could be hastened.  For this reason we investigated the role of 
angiotensin and AT1 receptor blockade by losartan. 
  
The pathology associated with LVH and the role of angiotensin.  Changes to myocardial function in 
humans are also associated with an increase of afterload, e.g. with aortic stenosis.  In the intact heart 
this can be manifest as increased QT dispersion [24], and in isolated tissues as prolongation of the 
action potential and slowed conduction [25].  Furthermore, regression of hypertrophy reduced the 
electrophysiological changes, but incompletely [24,26], and thus mirror results with our guinea-pig 
model. Many animal models of hypertrophy are associated with upregulation of the renin-
angiotensin system, with an increase of systemic angiotensin-II (AII) and aldosterone levels [27]. 
The evidence from this study is that angiotensin does not play a prominent role in the changes to 
electromechanical function associated with thoracic aortic constriction (AC).  Firstly, the changes 
occurring with angiotensin-induced hypertrophy were quite different from those evoked by AC.  
Secondly losartan had no effect, at the dose used (10 mg·kg-1·day-1) on changes evoked by AC, 
although it prevented completely the changes induced by angiotensin infusion.   
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Most studies using AT1 receptor antagonists and ACE inhibitors have focused on regression of 
hypertrophy itself, and fewer on their ability to reverse associated electromechanical changes.  In 
keeping with our conclusions, other observations have shown that losartan did not regress LVH 
associated with thoracic AC, nor improve contractile function [28,29].  Concerning other models of 
hypertrophy AT1 receptor blockade did not reverse electrophysiological changes, nor prevent the 
development of arrhythmias [30] or improve survival [31].  
 
Whether ACE inhibitors effect regression of LVH in this model requires further study.  In rats the 
ACE inhibitor perindropril prevented the age-related increase in HBR independent of its 
antihypertensive effects, but did not prevent APD prolongation [32].   However, chronic treatment 
of SHR rats with capropril restored APD with regression of hypertrophy [33]. Studies in other 
models of cardiac hypertrophy and failure have shown differential effects of ACE inhibition and 
AT1 receptor antagonism [34,35].  One possibility is that ACE inhibitors, but not AT1 receptor 
antagonists, inhibit degradation of bradykinin into non-active metabolites, as bradykinin itself can 
inhibit progression of hypertrophy [36].   
 
However, in hypertrophy generated by renovascular hypertension both AT1 receptor antagonists and 
ACE inhibitors normalize ventricular electrophysiology assessed by ventricular fibrillation 
thresholds, action potential duration and effective refractory periods [37-40]. This model is more 
similar to our angiotensin-infusion model, but it should be stressed that the electromechanical 
properties that we described above were not identical to those in this pressure-overload hypertrophy 
 
In conclusion, induction of LVH by different methods generates variable electromechanical changes 
to myocardium.  Regression of cardiac growth is not accompanied by complete recovery of 
function, and in particular electrophysiological changes that could predispose the heart to 
arrhythmias remain altered.  Losartan, at a dose sufficient to prevent angiotensin-induced LVH, had 
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no effect on regressing hypertrophy induced by thoracic aortic constriction, nor did it facilitate 
recovery of function during natural regression of cardiac growth.  Further studies may reveal if 
higher doses, or longer treatment periods with AT1 receptor blockers, ACE inhibitors or direct 
aldosterone blockers, affects electromechanical changes with aortic constriction. 
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Figure Legends 
 
Figure 1.  The experimental groups used in the study.  Groups 1-5 were animals undergoing two 
procedures at 0 and 42 days.  Groups 2-5 had as a first procedure aortic constriction; at day 42 the 
constriction was either left in place with a sham procedure (groups 2, 3), or removed (groups 4, 5).  
After the second procedure animals were gavaged with either saline (groups 2, 4) or losartan 
(groups 3, 5).  Group 1 animals had two sham-procedures and were age-matched controls.  
Experiments were carried out at day 84.  Groups 6-10 were animals undergoing one procedure at 
day 0.  Group 7 animals had aortic constriction, and were compared to sham-operated group 6 
animals.  Group 8-10 animals had osmotic mini-pump insertion, filled with saline (group 8) or 
angiotensin (groups 9, 10).  During this period animals were gavaged with saline (group 9) or 
losartan (group 10). 
 
 
 
Figure 2.  Electromechanical responses to angiotensin-II (AT) infusion and thoracic aortic 
constriction (AC).  A: The depolarising phases (upper traces) of action potentials propagating in the 
longitudinal (L) or transverse (T) axis of the preparation. The thicker lines (arrowed) over the 
experimental traces were analysed to calculate the time constant of the foot of the action potential, 
τap. Lower traces are the derivatives of the upper traces.  The conduction velocity was calculated as 
the ratio of distance between stimulating and recording electrodes and the delay d.  In the examples, 
from an 84-day aortic constricted (group 2) animal, the velocities were 59.6 cm·s-1 (L) and 22.4 
cm·s-1 (T).  B:  Values or the T1.6/0.8 twitch tension ratio; action potential duration (APD), 
longitudinal (θL) and transverse (θT) conduction velocities and the anisotropic conduction ratio, 
θL/θT in saline (Sal) or angiotensin-II (AT) infused animals, or aortic constricted animals (AC), 
groups 7-9, * p<0.05 with respect to saline, control values. Mean data ± SD, except APD95 values, 
mean ± SE.  C: Examples of action potentials recorded from a saline-infused animal (control), an 
angiotensin-II infused animal and a 42-day aortic-constricted animal.   
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Figure 3.  Heart-to-body weight ratios (HBR) of the experimental groups.  A: the effect of 
angiotensin-II infusion in the absence (AT) or presence of losartan (groups 8-10, figure 1).  B: The 
effect of feeding animals with saline or losartan during the period of 42-84 days aortic constriction 
(AC) – groups 1-3.  The effect or feeding losartan following de-banding (groups 1, 4, 5). * p<0.05 
with respect to sham-operated control values, § p<0.05 with respect to AC values. Mean data ± SD 
 
 
Figure 4. Electromechanical variables recorded in aortic-constricted (AC) animals fed with saline or 
losartan (groups 1-3).  Values of the T1.6/0.8 ratio; action potential duration (APD), longitudinal (θL) 
and transverse (θT) conduction velocities and the anisotropic conduction ratio, θL/θT are shown. * 
p<0.05 with respect to sham-operated control values. Mean data ± SD, except APD95 values, mean 
± SE. 
 
 
Figure 5. Electromechanical variables recorded in de-banded animals fed with saline or losartan 
(groups 1, 4 and 5). Values of the T1.6/0.8 ratio; action potential duration (APD), longitudinal (θL) 
and transverse (θT) conduction velocities and the anisotropic conduction ratio, θL/θT are shown.  For 
comparison the values recorded in age-matched aortic-constricted (AC) animals (group 2) are 
shown. * p<0.05 with respect to sham-operated control values, § p<0.05 with respect to AC values. 
Mean data ± SD, except APD95 values, mean ± SE. 
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FIGURE 2 
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Table 1: Measurements of heart weights during thoracic aorta constriction, de-banding of the 
aorta, and by angiotensin infusion. Values are mean ± S.D.  * denotes p<0.05 with respect to 
sham-operation.  § denotes p<0.05 de-banded with respect to aortic constriction. 
 
 
 
  
 
Heart-to-body weight 
ratio, g·kg-1 
Dried LV-to-body 
weight ratio, g·kg-1 
Sham-operation, 42 days, group 6 2.84±0.07 0.32±0.084 
Aortic constriction, 42 days, group 7 3.66±0.45 * 0.45±0.041 * 
Sham-operation, 84 days, group 1 2.79±0.09 0.33±0.028 
Aortic constriction, 84 days, group 2 3.92±0.45 * 0.51±0.044 * 
Aortic constriction, 42 days/de-banded, 42 
days group 4 
3.08±0.20 § 0.37±0.041 § 
Saline infusion, 42 days, group 8 2.66±0.24 0.32±0.080 
Angiotensin, 42 days, group 9 3.57±0.44 * 0.46±0.042 * 
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Table 2: Electromechanical properties of isolated myocardial preparations from 
control, aortic constricted and de-banded groups.  T(1.6/0.8), ratio of peak tension 
generated at 0.8 and 1.6 Hz; APD95, AP duration at 95% repolarisation.  θ, conduction 
velocity; Em, resting membrane potential; dV/dtmax, maximum AP upstroke velocity; τap, 
time constant of the foot of the AP.  Subscripts L and T refer to variables from action 
potentials conducting in the longitudinal or transverse axis of the preparation. Values are 
mean ± S.E.M., except θL, θT and the derived anisotropy ratio, θL/θT, which are mean ± S.D.  
* p<0.05 aortic constriction and de-banded with respect to sham-operation.  § p<0.05 de-
banded with respect to aortic constriction. #, p<0.05 transverse (T) vs longitudinal (L) for 
dV/dtmax and τap. 
 
 
 Sham-operation 
Group 1 
Aortic constriction 
Group 2 
De-banded  
Group 4 
T(1.6/0.8) 1.60±0.05 1.34±0.02 * 1.56±0.02 § 
APD95, ms 190±4 217±5 * 219±5 * 
θL, cm·s-1 72.4±1.4 59.6±4.3 * 67.3±4.1 *§ 
θT, cm·s-1 17.0±2.7 25.7±4.9 * 17.8±3.7 § 
θL/θT 4.38±0.76 2.37±0.32* 3.88±0.83 § 
Em, mV 84.5±0.6 85.4±1.0 84.7±0.4 
dV/dtmax (L), V·s-1  224±16 214±12 204±13 
dV/dtmax  (T), V·s-1 263±25 # 243±17 # 234±12 # 
τap (L), ms 0.31±0.026 0.30±0.016 0.33±0.014 
τap (T), ms 0.22±0.015 # 0.24±0.011 # 0.25±0.010 # 
 
 
 
 
 
 
 
